BridgeBio Pharma (BBIO) Gross Profit (2020 - 2026)

BridgeBio Pharma has reported Gross Profit for 7 years, with the latest figure at $184.6 million in Q1 2026.

• Quarterly Gross Profit rose 61.92% year-over-year to $184.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $551.7 million (up 354.09% YoY) and the FY2025 annual result came in at $481.1 million, up 120.67% from the prior year.
• Gross Profit improved to $184.6 million in Q1 2026 per BBIO's latest filing, from $146.1 million in the prior quarter.
• Over five years, Gross Profit peaked at $210.5 million in Q1 2024 and troughed at -$401000.0 in Q3 2022.
• A 5-year average of $56.8 million and a median of $3.5 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2024: Gross Profit tumbled 145.06% in 2022, then surged 17816.77% in 2024.
• Over 5 years, Gross Profit stood at $1.2 million in 2022, then decreased by 6.21% to $1.1 million in 2023, then soared by 231.12% to $3.8 million in 2024, then jumped by 3746.0% to $146.1 million in 2025, then grew by 26.36% to $184.6 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $184.6 million, $146.1 million, and $114.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.